Identification of ZG16B as a prognostic biomarker in breast cancer-Reference-Cited by-同舟云学术

Identification of ZG16B as a prognostic biomarker in breast cancer

Published:2020-01-01 Issue:1 Volume:16 Page:1-13
ISSN:2391-5463
Container-title:Open Medicine
language:en
Short-container-title:

Author:

Lu Haotian¹,Shi Chunying²,Liu Xinyu¹,Liang Chen¹,Yang Chaochao¹,Wan Xueqi¹,Li Ling²,Liu Ying¹³

Affiliation:

1. School of Basic Medicine, College of Medicine, Qingdao University , Qingdao , 266071 , China

2. Department of Human Anatomy, Histology and Embryology, School of Basic Medicine, College of Medicine, Qingdao University , Qingdao , 266071 , China

3. Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University , Qingdao , 266071 , China

Abstract

Abstract Zymogen granule protein 16B (ZG16B) has been identified in various cancers, while so far the association between ZG16B and breast cancer hasn’t been explored. Our aim is to confirm whether it can serve as a prognostic biomarker in breast cancer. In this study, Oncomine, Cancer Cell Line Encyclopedia (CCLE), Ualcan, and STRING database analyses were conducted to detect the expression level of ZG16B in breast cancer with different types. Kaplan–Meier plotter was used to analyze the prognosis of patients with high or low expression of ZG16B. We found that ZG16B was significantly upregulated in breast cancer. Moreover, ZG16B was closely associated with foregone biomarkers and crucial factors in breast cancer. In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.

Publisher

Walter de Gruyter GmbH

Subject

General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/med-2021-0004/pdf

Reference98 articles.

1. DeSantis CE, Ma J, Sauer AG, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. Ca-a Cancer J Clinic. 2017;67(6):439–48.

2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. Ca-a Cancer J Clinic. 2016;66(2):115–32.

3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. Ca-a Cancer J Clinic. 2016;66(1):7–30.

4. Liu Y, Ao X, Jia Z, Bai XY, Xu Z, Hu G, et al. FOXK2 transcription factor suppresses ERalpha-positive breast cancer cell growth through down-regulating the stability of ERalpha via mechanism involving BRCA1/BARD1. Sci Rep. 2015;5:8796.

5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptomics in idiopathic pulmonary fibrosis unveiled: a new perspective from differentially expressed genes to therapeutic targets;Frontiers in Immunology;2024-03-19

2. Ferroptosis, Metabolic Rewiring, and Endometrial Cancer;International Journal of Molecular Sciences;2023-12-20

3. Molecular Subtypes and Machine Learning-Based Predictive Models for Intracranial Aneurysm Rupture;World Neurosurgery;2023-11

4. An emphasis on the interaction of signaling pathways highlights the role of miRNAs in the etiology and treatment resistance of gastric cancer;Life Sciences;2023-06

5. FADD as a key molecular player in cancer progression;Molecular Medicine;2022-11-08